ARQT - Arcutis Biotherapeutics, Inc.
IEX Last Trade
14.97
4.570 30.528%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:18:29 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$10.40
4.57
43.94%
Fundamental analysis
25%
Profitability
25%
Dept financing
16%
Liquidity
75%
Performance
15%
Performance
5 Days
0 0%
1 Month
39.18%
3 Months
64.73%
6 Months
56.15%
1 Year
406.42%
2 Year
4.83%
Key data
Stock price
$14.97
DAY RANGE
$10.40 - $15.08
52 WEEK RANGE
$3.32 - $15.79
52 WEEK CHANGE
$396.36
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Todd F. Watanabe
Region: US
Website: arcutis.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: arcutis.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of arq-154.
Recent news